# Efficacy and Safety of Toripalimab Combined With Docetaxel or Nab-paclitaxel in Patients With Advanced Gastric Cancer

> **NCT04563975** · PHASE2 · UNKNOWN · sponsor: **Tao Zhang** · enrollment: 54 (estimated)

## Conditions studied

- Gastric Cancer Stage IV

## Interventions

- **DRUG:** Toripalimab
- **DRUG:** Docetaxel
- **DRUG:** nab-paclitaxel

## Key facts

- **NCT ID:** NCT04563975
- **Lead sponsor:** Tao Zhang
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2020-07-02
- **Primary completion:** 2022-12-31
- **Final completion:** 2023-05-30
- **Target enrollment:** 54 (ESTIMATED)
- **Last updated:** 2021-03-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04563975

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04563975, "Efficacy and Safety of Toripalimab Combined With Docetaxel or Nab-paclitaxel in Patients With Advanced Gastric Cancer". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT04563975. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*